OSR Holdings, Inc.(OSRHW),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

OSRHW OSR Holdings, Inc.

Market Closed 04-17 16:00:00 EDT

0.0389

+0.0022

+5.99%

High0.0393	Low0.0311	Vol1.66K
Open0.0311	D1 Closing0.0367	Amplitude22.34%
Mkt Cap0.00	Tradable Cap0.00	Total Shares0.00
T/O62.61	T/O Rate--	Tradable Shares0.00
P/B--	ROE--	EPS0.00
52wk High0.2089	52wk Low0.0197	P/E--
Dividend0.00	Div.Yield0.00	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"OSRHW","market":"US","secType":"STK","nameCN":"OSR Holdings, Inc.","latestPrice":0.0389,"timestamp":1744920000000,"preClose":0.0367,"halted":0,"volume":1662,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":0.0022,"latestTime":"04-17 16:00:00 EDT","open":0.0311,"high":0.0393,"low":0.0311,"amount":62.6122,"amplitude":0.223433,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":0.0367,"volumeRatio":0.41320671615456045},"requestUrl":"/m/hq/s/OSRHW","defaultTab":"news","newsList":[{"id":"2524253456","title":"OSR Holdings, Inc. (NASDAQ: OSRH) Enters Into $80 Million Common Stock Purchase Agreement With White Lion GBM Innovation Fund, With An Eye Towards Leveraging Innovate GBM's Non-Profit Ecosystem to Accelerate Glioblastoma Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2524253456","media":"PR Newswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524253456?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 19:30","pubTimestamp":1743679800,"startTime":"0","endTime":"0","summary":"SEOUL, South Korea, April 3, 2025 /PRNewswire/ --OSR Holdings, Inc.  , a global healthcare company focused on advancing innovative therapies, today announced that it has entered into a Common Stock Purchase Agreement with White Lion GBM Innovation Fund . Under this agreement, OSR has the right, but not the obligation, to sell up to $80 million in common stock to Innovation Fund over time, which will prospectively provide OSR with critical funding to accelerate its mission of improving patient outcomes worldwide.\"We anticipate that this collaboration with Innovation Fund will also introduce our Vaximm VXM01 program into Innovate GBM's ecosystem of researchers, clinicians, regulatory experts, investors, policymakers, and patient advocates; the same ecosystem that initially connected OSR and Innovation Fund. Together, we are committed to transforming glioblastoma treatment from a fragmented approach to one characterized by cooperation, transparency, and progress,\" said Constance Hfer, CSO","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/osr-holdings-inc-nasdaq-osrh-113000232.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/osr-holdings-inc-nasdaq-osrh-113000232.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","TQQQ","QID","OSRH","IE00B64PRP62.GBP","NVIW.SI","NQmain","PSQ","AAQC",".IXIC","SQQQ","USAW.SI","BK4585","MNQmain","LU2210150020.SGD","USJW.SI","IE00BKPKM429.USD","LU2210149790.SGD","OSRHW","BK4588","IE00B3QW5Z07.USD","BK4112","LU2095319765.USD","TSYW.SI","NDAQ","QLD","IE00BGHQF748.EUR"],"gpt_icon":1},{"id":"2522875506","title":"Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2522875506","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522875506?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 19:16","pubTimestamp":1742987760,"startTime":"0","endTime":"0","summary":"Results from Phase 2a Trial demonstrate a good safety and tolerability profile of VXM01 and Avelumab Combination Therapy in Glioblastoma, supporting further investigation of VXM01. The VXM01-avelumab combination therapy was generally well-tolerated, with the majority of safety events being mild to moderate in severity. These safety and tolerability data are in-line with previously reported data onavelumab alone with no additional safety signals for the combination of VXM01 and avelumab.No serious adverse events were attributed to VXM01, while9 of 11  were related to the target disease, underscoring the well manageable safety profile of this combination therapy in a frail patient population.The reported safety and tolerability data, together with early indications for the potential relevance of a VXM01dependent, VEGFR-2 specific immune response in GBM therapy warrant further study.\"The completion of this Phase 2a study is a significant mi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/vaximm-ag-osr-company-announces-111600323.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vaximm-ag-osr-company-announces-111600323.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AG","BK4139","OSRHW","OS","OSRH","BK4210","BK4097","ORR"],"gpt_icon":0},{"id":"2522023397","title":"OSR Holdings Appoints Dr. Constance Höfer as Chief Scientific Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2522023397","media":"PR Newswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522023397?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 19:00","pubTimestamp":1742900400,"startTime":"0","endTime":"0","summary":"BASEL, Switzerland, March 25, 2025 /PRNewswire/ --OSR Holdings, Inc. , a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families, today announced the appointment of Dr. Constance Hfer as its new Chief Scientific Officer . Dr. Hfer, a seasoned leader in drug development with over 20 years of experience in oncology and immunology, will oversee OSR Holdings' scientific strategy and innovation pipeline.Dr. Hfer joins OSR Holdings from Merck Healthcare, where she led global programs spanning from preclinical to late-stage clinical development. Prior to Merck, she held senior leadership positions at Sandoz Biopharmaceuticals, Priaxon AG, and Medigene AG, playing a key role in advancing therapeutic programs across various modalities, including New Biological Entities , New Chemical Entities , nucleotides, and viral and cell-based therapies.Regarding her new appointment, Dr. Hfer said \"I am honored to join the disting","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/osr-holdings-appoints-dr-constance-110000172.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/osr-holdings-appoints-dr-constance-110000172.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OSRHW","OSRH","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bellevuespac.com","stockEarnings":[{"period":"1week","weight":0.0514},{"period":"1month","weight":0.0542},{"period":"3month","weight":-0.0275},{"period":"6month","weight":0.7406},{"period":"1year","weight":0.945},{"period":"ytd","weight":-0.1879}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Bellevue Life Sciences Acquisition Corp. focuses on effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The company intends to acquire companies in the healthcare industry. Bellevue Life Sciences Acquisition Corp. was founded in 2020 and is based in Bellevue, Washington. Bellevue Life Sciences Acquisition Corp. operates as a subsidiary of Bellevue Global Life Sciences Investors LLC.","exchange":"NASDAQ","name":"OSR Holdings, Inc.","nameEN":"OSR Holdings, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"OSR Holdings, Inc.(OSRHW),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest OSR Holdings, Inc.(OSRHW) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"OSR Holdings, Inc.,OSRHW,OSR Holdings, Inc.股票,OSR Holdings, Inc.股票老虎,OSR Holdings, Inc.股票老虎国际,OSR Holdings, Inc.行情,OSR Holdings, Inc.股票行情,OSR Holdings, Inc.股价,OSR Holdings, Inc.股市,OSR Holdings, Inc.股票价格,OSR Holdings, Inc.股票交易,OSR Holdings, Inc.股票购买,OSR Holdings, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"OSR Holdings, Inc.(OSRHW),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest OSR Holdings, Inc.(OSRHW) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction